BioMarin Pharmaceutical Inc.

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

21 Jul 2020 10:35:26 By NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

20 Jul 2020 10:19:11 By NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

13 Jul 2020 10:04:13 By NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

07 Jul 2020 10:01:55 By NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

01 Jul 2020 14:14:26 By NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

19 Jun 2020 10:03:02 By NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

18 Jun 2020 09:45:01 By NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

17 Jun 2020 12:52:05 By NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

04 Jun 2020 09:55:24 By NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

03 Jun 2020 13:00:45 By NetDania Notify

NetDania - New 12 months High: BioMarin Pharmaceutical Inc.

26 May 2020 09:45:09 By NetDania Notify

BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia

12 Dec 2016 08:29:22 By Nasdaq GlobeNewswire

BioMarin to Attend Three Upcoming Investor Conferences

03 Nov 2016 08:30:46 By Nasdaq GlobeNewswire

BioMarin Announces Third Quarter 2016 Financial Results

27 Oct 2016 16:03:46 By Nasdaq GlobeNewswire

BioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 Meeting

19 Oct 2016 17:01:21 By Nasdaq GlobeNewswire

UK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia A

13 Oct 2016 16:01:29 By Nasdaq GlobeNewswire

BioMarin to Host Third Quarter 2016 Financial Results Conference Call and Webcast on Thursday, October 27 at 4:30pm ET

11 Oct 2016 08:31:09 By Nasdaq GlobeNewswire

BioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases against Sarepta Therapeutics

21 Sep 2016 08:54:15 By Nasdaq GlobeNewswire

BioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten Disease

15 Sep 2016 08:38:09 By Nasdaq GlobeNewswire

BioMarin Announces Two Oral and 16 Poster Presentations at Society for the Study of Inborn Errors of Metabolism 2016 Annual Meeting

08 Sep 2016 04:30:29 By Nasdaq GlobeNewswire